SCHEMBL3281242

SCHEMBL3281242

Cc1cccc(C(=O)Cc2ccsc2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.45
CTNNB1 P35222 2/20 0.43
WNT3A P56704 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
HPGD P15428 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
POLB P06746 1/20 0.42
GRM1 Q13255 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
FFAR1 O14842 1/20 0.42
TP53 P04637 1/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6359073 0.80 CTBP2 (0.54) PARP1CTNNB1WNT3ASMN1; SMN2TDP1
SCHEMBL359526 0.80 L3MBTL1 (0.49) SMN1; SMN2TDP1HPGDNPC1RAB9A
SCHEMBL11382971 0.79 RAB9A (0.57) PARP1CTNNB1WNT3ASMN1; SMN2HTT
SCHEMBL3289372 0.79 L3MBTL1 (0.58) PARP1CTNNB1WNT3ASMN1; SMN2HTT
Hydrochloric Acid SCHEMBL27642400 0.79 L3MBTL1 (0.48) SMN1; SMN2TDP1HPGDNPC1RAB9A
SCHEMBL16171153 0.78 MEN1 (0.52) PARP1CTNNB1WNT3ASMN1; SMN2HTT
SCHEMBL3896133 0.75 PARP1 (0.47) PARP1CTNNB1WNT3ASMN1; SMN2HTT
SCHEMBL3073424 0.75 NT5E (0.55) PARP1CTNNB1WNT3ASMN1; SMN2TDP1
SCHEMBL3281032 0.75 KDM4E (0.58) PARP1CTNNB1WNT3ASMN1; SMN2HTT
SCHEMBL10370870 0.74 PARP1 (0.50) PARP1SMN1; SMN2TDP1HPGDHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2018364-B1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN INC (US) 2013-08-21 EP disclosed
US-7709507-B2 Therapeutic fluoroethyl ureas ALLERGAN, INC. (US) 2010-05-04 US disclosed
EP-2018364-A1 THERAPEUTIC FLUOROETHYL UREAS Allergan, Inc. (US) 2009-01-28 EP disclosed
WO-2007137029-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. (US) 2007-11-29 WO disclosed
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS ALLERGAN, INC. 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270498-A1 THERAPEUTIC FLUOROETHYL UREAS SLC14A1, MAPT, UTS2R PARP1 3544/4885CTNNB1 2463/4885WNT3A 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.